Quillaja.
Soapbark saponins that foam in water. In a supplement their job is usually holding oil and water together in the formula rather than acting on anything in your body.
- Category
- Herb
What Quillaja is, and what it does.
- Does it work
- It suits formulators who need a plant emulsifier or foaming agent. As an active ingredient for people, the research sits mostly in poultry, pigs and farmed fish.
- How much to take
- No dose figure is on record for people. It works at low use levels as a foaming and clouding agent, because of how strongly it lowers surface tension.
- Time to feel it
- Its effect shows up in the formulation, as a stable emulsion and a lasting foam, rather than on a personal timeline. Human time-course studies haven't been done.
- The first dose
- Day one shows up in the drink or capsule rather than in you: a stable cloud and a persistent head. No day-one human effect has been documented.
- With regular use
- Long-term human intake at food-use levels hasn't been studied. What is established is that saponins bind cholesterol and bile salts in the gut lumen.
- How well tolerated
- Well tolerated at the low levels used in food and drink. Larger amounts can irritate the gut, and injected uses are a pharmaceutical matter rather than a supplement one.
- How it feels
- Soapy and slightly bitter if you taste it neat. In a finished product you notice texture and foam, not a sensation in your body.
- The overlooked benefit
- Because saponins are amphiphilic, they help carry fat-soluble compounds into a water-based formula, which is why they turn up alongside vitamin E and coenzyme Q10.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- emulsifying and foaming in beveragesNarrative review
- binding of cholesterol and bile salts in the gut lumenAnimal study
- membrane permeability and haemolytic activity of saponinsIn vitro study
- adjuvant activity of the purified QS-21 fraction when injected with an antigenRandomised trial
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Saponins from Quillaja bark carry a hydrophobic triterpene core and hydrophilic sugar chains, so they lower interfacial tension and stabilise oil-in-water emulsions at low concentrations. That is why they appear in beverage emulsions carrying tocopherols. A finer, more stable emulsion droplet generally presents more surface for lipase and micelle formation. This is physical chemistry and formulation behaviour, not a measured rise in human tocopherol status.
Ubiquinone dissolves poorly in the aqueous gut and its uptake tracks how well it is dispersed before it arrives. Quillaja extract is a food-grade natural emulsifier used to hold lipophilic actives in fine droplets in liquid formats. The mechanism is dispersion, which is a formulation property rather than a claim about blood levels. Whether a Quillaja-emulsified format raises plasma ubiquinone in people has not been shown.
Beta-carotene crystallises out of water and needs an emulsifier and an oil phase to stay suspended. Quillaja saponin is used in exactly this role in beverage systems, where it also produces the cloud effect. Better dispersion is a prerequisite for absorption, though it is not the same thing as absorption. No human uptake comparison specific to Quillaja-emulsified carotenoids is available here.
Triterpene saponins complex with cholesterol and with bile salt micelles inside the gut lumen, and plant sterols compete for space in those same micelles. Given together, the two act on the same luminal step by different routes. The direction is additive in mechanism. Human co-administration data for Quillaja specifically is not available, so this stays mechanistic.
A pig feeding trial compared dietary Quillaja saponin against phytase for effects on growth and nutrient digestibility, so the two sit in the same additive category in animal nutrition. Phytase releases phosphorus bound in phytate while saponin acts on membrane and lumen surfaces, which are unrelated routes. The pairing is a research convention rather than a demonstrated interaction. None of this was measured in people.
Quillaja and Yucca schidigera supply different saponin classes, triterpene and steroidal respectively, and a broiler study tested them as a fixed combination on performance and carcass traits. Commercial saponin additives frequently blend the two for that reason. The evidence is in birds under production conditions, not in humans. Anyone reading it across to people is extrapolating well past the data.
Saponins are known to interact with intestinal brush-border membranes and to complex with luminal components, and saponin-rich plant materials are commonly discussed as anti-nutritional factors for mineral status. The direction of any effect on iron would depend on dose and food matrix. Flagging it is prudent when a formula deliberately adds a saponin surfactant alongside minerals. Direct human measurement of Quillaja against iron status is not available here.
Nothing specific on file for Quillaja. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Quillaja actually does.
Quillaja bark's saponins have both a water-loving and an oil-loving end, which lets them act as surfactants that lower surface tension and help oil and water mix at low amounts.
These saponins bind to cholesterol and bile salts in the gut, which is behind both their foaming ability and why they're classically labeled as anti-nutritional in animal feed.
At high enough concentration, saponins interact with sterols in cell membranes and make them more permeable, which is the basis of their activity against red blood cells seen in lab studies, and why injectable use belongs to specialist pharmaceutical work rather than supplements.
A purified fraction called QS-21 is used as a vaccine booster that amplifies immune response to a co-given antigen, but that's an injected drug application and doesn't carry over to an oral bark extract in food or supplements.
Where Quillaja comes from.
Soapbark from a Chilean tree. It foams in water, which is why it shows up in fizzy drinks and why people have washed with it for centuries. In supplements its job is almost always to hold oil and water together rather than to do anything itself. Nearly all the research is in chickens, pigs and farmed fish, so anyone quoting it as a human ingredient is stretching.
Made from a plant. What ends up in the capsule tracks the harvest, so batch testing and a stated marker matter more here than with a made molecule.
An evergreen tree native to central Chile. Harvest is regulated in Chile and increasingly comes from managed plantations and from wood and branch material rather than felled wild trees.
Milled bark is extracted with water, then filtered to remove fibre. The crude extract carries saponins plus tannins and polysaccharides.
Membrane steps strip tannins and colour. Chromatographic separation is what produces defined single saponins such as QS-21 for pharmaceutical use.
Commercial grades are declared by saponin percentage. Crude beverage grades and purified concentrates differ by an order of magnitude in that figure.
Sold as a concentrated liquid or dried onto a carrier. Use levels in food and beverage are in the parts-per-million range.
The forms it comes in.
The essence, in one line each.
- Dietary Quillaja saponin or phytase was assessed for growth performance and nutrient digestibility in the study animals.Animal study. Li T et al., 2025 (Journal of Animal Physiology and Animal Nutrition). PMID 39264744 ↗
- A quillaja and yucca combination was evaluated for performance and carcass traits in coccidia-vaccinated broilers.Randomised trial. Bafundo KW et al., 2021 (Poultry Science). PMID 34428644 ↗
- Dietary Quillaja saponaria was examined for effects on muscle colour, oxidative stability and volatile profile.Animal study. Nasri S et al., 2012 (Meat Science). PMID 22771112 ↗
- Quillaja saponaria extracts were investigated for antiviral application in Atlantic salmon.Animal study. Schlotterbeck T et al., 2026 (Frontiers in Veterinary Science). PMID 41696010 ↗
- Essential oils and saponins, alone and combined, were assessed for productive performance and intestinal morphology. Saponins are named within a broader additive comparison.Animal study. Youssef IMI et al., 2021 (Journal of Animal Physiology and Animal Nutrition). PMID 32755039 ↗
- Digestibility and tissue transcriptomic profiling were reported in supplemented laying hens, with saponin-type additives named among the supplements discussed.Animal study. Reyer H et al., 2026 (Poultry Science). PMID 41418532 ↗
- A liposomal antigen presentation system elicited cellular immunity in the model used, with saponin adjuvant chemistry referenced in the formulation context.Animal study. Kim SY et al., 2026 (Immune Network). PMID 42109605 ↗
These are the studies our verdict leans on, chosen from the 7 we read for Quillaja. The full linked list is below.
The studies, linked.
4 sources behind our Quillaja verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialTo Test the Efficacy of Novel Berberine Emulsification by TPGS or Quillaja Extract on the Absorption of Berberine Compared to Berberine Powder in HumansClinicalTrials.gov ↗32 participants, Completed
- Clinical trialA Proof-of-concept, Feasibility Study to Investigate the Effect of Cranberry and Quillaia Extract Type II on Symptoms in Women With Uncomplicated Urinary Tract Infection and to Study the Modulation of the Urinary and Gut Microbiome Pre- and Post-antibiotic UseClinicalTrials.gov ↗Phase 2, 2 participants, Terminated
- Clinical trialThe Effect of the Consumption of 4 Botanical Extracts (Acerola, Panax Ginseng, Echinacea, Quillaja) on the Innate and Adaptive Immune Response in Healthy Adults: a Pilot Randomized Placebo-controlled Clinical TrialClinicalTrials.gov ↗115 participants, Unknown
- Clinical trialA Phase 1B Double Blinded Randomized Trial Evaluating Safety, Tolerability, and Immune Response of OSU-2131 a BZLF1 Peptide Vaccine With Stimulon™ QS-21 Solution Adjuvant in Healthy Volunteers and Patients Awaiting Solid Organ TransplantationClinicalTrials.gov ↗Phase 1, 55 participants, Recruiting
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.